The demand within the global market for scleroderma diagnostics and therapeutics has been rising on account of advancements in the field of rheumatoid treatments, finds Transparency Market Research (TMR). Several old and new vendors have introduced a plethora of business strategies in the global scleroderma diagnostics and therapeutics market in recent times. The presence of well-equipped market vendors who have state of the art research facilities is a key highlight of the market’s competitive landscape. The need for seamless growth within the global market for scleroderma diagnostics and therapeutics has led industry leaders to abolish barriers to market entry. Hence, a number of new vendors are expected to enter the global scleroderma diagnostics and therapeutics market in the years to come.
The leading vendors in the global scleroderma diagnostics and therapeutics market are projected to invest in new avenues for growth and development. This includes better research, stronger ties with hospitals and healthcare centers, and bonds with pharmaceutical companies. The market for scleroderma diagnostics and therapeutics is also expected to witness new growth strategies being introduced by the small and medium scale-vendors. Some of the key players in the global scleroderma diagnostics and therapeutics market are Cytori Therapeutics, Inc., Cumberland Pharmaceuticals, Inc., Corbus Pharmaceutical Holdings Inc, and Gilead Sciences, Inc.
Transparency Market Research (TMR) finds that the global scleroderma diagnostics and therapeutics market would expand at a stellar CAGR of 10.3% over the period between 2017 and 2024. Furthermore, the market for scleroderma diagnostics and therapeutics is expected to accumulate revenues worth S$3,663.8 mn by 2024, rising up from a value of US$1,689.7 mn in 2017. Based drug class, the demand for corticosteroids is projected to increase at a rapid pace in the coming times. On the basis of geography, the market for scleroderma diagnostics and therapeutics in North America is slated to expand at a healthy CAGR.
Request a PDF Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2498
Popularity of Skin Diagnostic Tests to Aid Market Growth
The demand within the global market for scleroderma diagnostics and therapeutics has been rising on account of advancements in the field of skin diagnostics. Scleroderma diagnostics have gained traction across multiple domains within the healthcare industry in recent times. This owes to the relevance of such diagnostics for the overall health of patients. Moreover, skin biopsies have also become extremely common across the medical fraternity which has in turn aided market growth. The popularity of various types of imaging techniques has created a plethora of opportunities within the global scleroderma diagnostics and therapeutics market. Need for improved diagnostics for cardiac care shall also aid market growth.
Growing demand for Electrocardiogram to Propel Demand
The use of electrocardiogram has increased in the recent times as incidence of heart disorders is rising. Since tests related to electrocardiogram come under scleroderma diagnostics and therapeutics, the global market has reaped key revenues via the aforementioned trend. Furthermore, the need for pulmonary function tests has also generated commendable demand within the global scleroderma diagnostics and therapeutics market. It is expected that the growing popularity of echocardiogram would also play to the advantage of the global scleroderma diagnostics and therapeutics market.
The review is based on TMR;s report titled, “Scleroderma Diagnostics and Therapeutics Market (Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, and ACE Inhibitors; Indication - Localized and Systemic; Diagnostic Test Type - Skin Biopsy, Imaging Techniques, Blood Test, Electrocardiogram and Echocardiogram, and Pulmonary Function Tests) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2024”.
The global scleroderma diagnostics and therapeutics market is segmented as follows:
Global Scleroderma Therapeutics Market, by Drug Class
- Immunosuppressive Agents
- Endothelin Receptor Agonists
- Calcium Channel Blockers
- PDE-5 Inhibitors
- Chelating Agents
- Prostacyclin Analogues
- Others (H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors etc.)
Global Scleroderma Therapeutics Market, by Indication
Global Scleroderma Diagnostics Market, by Test Type
- Skin Biopsy
- Imaging Techniques
- Blood Tests
- Electrocardiogram and Echocardiogram
- Pulmonary Function Tests
Global Scleroderma Diagnostics and Therapeutics Market, by Geography
- North America
- Asia Pacific
- Rest of APAC
- Rest of Europe
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453